Close Menu

This story has been updated to include comments from a conference call with investors.

NEW YORK – Meridian Bioscience reported on Friday that its fiscal fourth quarter revenues increased 26 percent year over year, with reagent sales more than offsetting a dip in diagnostics revenues.

For the three months ended Sept. 30, the firm reported revenues of $64.2 million up from $50.8 million a year ago and beating the average consensus Wall Street estimate of $59.6 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.